Form D · Biotechnology

Numerion Labs, Inc.

San Francisco, CA · CIK 0001736153

Offering snapshot reported Mar 19, 2026 · SEC filing

Reported sold: $19.8M
Investors reported: 5
Minimum accepted: $0
First sale: Mar 10, 2026

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Mar 19, 2026	Initial	$19,794,945	No comparison	5	SEC filing
Mar 14, 2025	Initial	$44,282,650	No comparison	19	SEC filing
Aug 11, 2020	Initial	$123,010,086	No comparison	25	SEC filing
Jul 2, 2018	Initial	$51,492,758	No comparison	31	SEC filing

Offering details

Securities: Equity, Other
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-577049

Offer and sale of Series D Preferred Stock and Common Stock issuable upon conversion thereof. Certain outstanding shares of Common Stock were exchanged for shares of a specific series of Issuer's Preferred Stock for no consideration.

Source: Form D, filed Mar 19, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Raj Ganguly	Director
Abraham Heifets	Director, Executive
Han Lim	Executive
Linda Maxwell	Director
Robert Mittendorff	Director
Matt Ocko	Director
Adam Seabrook	Director
Kiersten Stead	Director
Gavin Teo	Director
Mike Varney	Director
Izhar Wallach	Director
Stephen Worland	Director, Executive
Yan Zhao	Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

250 Sutter St. Suite 650
San Francisco, CA, 94108